NGM BIOPHARMACEUTICALS INC's ticker is NGM and the CUSIP is 62921N105. A total of 89 filers reported holding NGM BIOPHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 2.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $19,406,306 | -58.7% | 18,136,735 | 0.0% | 12.88% | -29.3% |
| Q2 2023 | $46,974,144 | -36.5% | 18,136,735 | 0.0% | 18.23% | -31.9% |
| Q1 2023 | $73,997,879 | -18.7% | 18,136,735 | 0.0% | 26.76% | -11.7% |
| Q4 2022 | $91,046,410 | -61.6% | 18,136,735 | 0.0% | 30.31% | -42.3% |
| Q3 2022 | $237,228,000 | +2.0% | 18,136,735 | 0.0% | 52.50% | +6.1% |
| Q2 2022 | $232,513,000 | -6.1% | 18,136,735 | +11.6% | 49.48% | +7.7% |
| Q1 2022 | $247,749,000 | -9.1% | 16,245,817 | +5.5% | 45.93% | +23.9% |
| Q4 2021 | $272,665,000 | -15.7% | 15,396,116 | 0.0% | 37.08% | +0.7% |
| Q3 2021 | $323,626,000 | +6.6% | 15,396,116 | 0.0% | 36.81% | -14.3% |
| Q2 2021 | $303,611,000 | -32.2% | 15,396,116 | 0.0% | 42.97% | +0.2% |
| Q1 2021 | $447,565,000 | -4.1% | 15,396,116 | 0.0% | 42.88% | +1.3% |
| Q4 2020 | $466,502,000 | – | 15,396,116 | – | 42.31% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Column Group LLC | 18,136,735 | $237,228,000 | 52.50% |
| Ponoi II Management, LLC | 1,298,908 | $16,990,000 | 44.41% |
| Ponoi Management, LLC | 1,298,908 | $16,990,000 | 23.20% |
| Euclidean Capital LLC | 746,674 | $9,766,000 | 9.07% |
| StepStone Group LP | 1,573,357 | $20,580,000 | 2.93% |
| Logos Global Management LP | 850,000 | $11,118,000 | 1.37% |
| First Light Asset Management, LLC | 955,505 | $12,498,000 | 1.26% |
| GREAT POINT PARTNERS LLC | 316,256 | $4,137,000 | 1.00% |
| Rubric Capital Management LP | 877,161 | $11,473,000 | 0.58% |
| Avidity Partners Management LP | 1,798,100 | $23,519,000 | 0.48% |